NAD+ PRECURSORS FOR USE IN THE PREVENTION AND/OR TREATMENT OF HEREDITARY AORTIC ANEURYSMS

Pharmaceutical compound that allows reversing or stopping aortic aneurysms of genetic origin or due to risk factors, avoiding the use of invasive surgical interventions, in addition to preventing the sudden death of many patients with aortic aneurysms. ​Although hereditary aortic aneurysms are diseases that exhibit significant etiology differences, the present invention shows that contractile phenotype changes that occur in these hereditary diseases are modulated by a decline in mitochondrial metabolism of vascular smooth muscle cells (CMLVs) and that​, enhancing mitochondrial metabolism is a therapeutic approach suitable for resetting the homeostasis of CMLVs and preventing the evolution and development of aortic aneurysms in such patients. In the present invention, the nicotinamide adenine dinucleotide (NAD +) precursors are described as being capable of increasing mitochondrial respiration function, preventing and providing treatment for diseases that cure with poor mitochondrial respiration and​, namely, for the prevention of the appearance and treatment of hereditary aortic aneurysms. ​Thus, the present invention relates to a dinucleotide adenine dinucleotide (NAD +) precursor, for use in preventing the onset and/or treatment of a hereditary etiology aortic aneurysm (AAH) which is characterized by the presence of poor mitochondrial respiration.